
Event details
Governance mechanisms, acceptability, and trust in medical AI by Nicholson Price
Description
Given the tremendous potential and rapid adoption of AI systems for health, how can we ensure that they are safe and effective, both in design and in implementation? Two key mechanisms are often promoted by policymakers, professional organizations, and scholars: centralized regulation and patient-level oversight by expert humans in the loop. But it is a dangerous mistake to design AI systems or AI regulation with the assumption that these two mechanisms can be combined for an effective oversight regime for medical AI. Each mechanism has major limitations: centralized governance has limited ability to address localization and generalizability challenges that are endemic to medical AI, and humans in the loop are often quite bad at overseeing AI decisions--when they are available for that oversight in the first place. This talk will explore the theoretical limitations to these mechanisms and also consider their implications for patient trust and acceptance of AI systems.
Registration
Register
Organized by Lifesciencelaw.dk and CeBIL - Centre for Advanced Studies in Biomedical Innovation Law.
Having issue with registation?
Try copy and paste the link below in your browser
https://jura.ku.dk/cebil/calendar/2025/governance-mechanisms-acceptability-and-trust-in-medical-ai/
Additional details
Metro stop: Islands Brygge
Parking: See registration link
Meet the speakers
Nicholson Price is a professor of law at the University of Michigan. He teaches and writes in the areas of intellectual property, health law, and regulation, particularly focusing on the law surrounding innovation in the life sciences. He has an extensive collection of colorful bow ties.
He is a research fellow at the University of Copenhagen’s Center for Advanced Studies in Bioscience Innovation Law and co-principal investigator of the Project on Precision Medicine, Artificial Intelligence, and the Law.
Price previously was an assistant professor of law at the University of New Hampshire School of Law; an academic fellow at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School; and a visiting scholar at the University of California, Hastings College of the Law.